| NCT04209855 | III | Platinum resistant FRalpha+ high grade serous ovarian cancer, excluding primary platinum refractory | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | AL, AK, AZ, CA, CO, CT, FL, GA, IL, IN, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WV | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT04296890 | III | Platinum resistant FRalpha+ ovarian cancer with prior bevacizumab; excluding primary platinum refractory | SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | AZ, CA, CO, FL, GA, IL, IN, KS, KY, LA, MD, MA, MO, NV, NJ, NY, TN, TX, WA, WI | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT03552471 | I | Recurrent FRalpha+ ovarian cancer, excluding platinum-sensitive at first recurrence and primary platinum refractory (in expansion) | Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | OH | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials | Rucaparib | Rubraca, CO-338, PF 01367338, AG-014699 | PARP inhibitor | Approved in Ovarian Cancer |
|
|